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Abstract 1 
 2 
 3 
Background. 4 
Research suggests that schizophrenia, which is linked to a range of physical health conditions, may share 5 
intrinsic inflammatory disease pathways with type-two diabetes mellitus. However, psychotropic 6 
medication, which can adversely affect metabolic indices, has presented a major confounder in examining 7 
this association. First-episode psychosis patients present an interesting cohort to study this potential 8 
association, being generally younger with therefore less comorbidity to confound associations, and 9 
having had limited exposure to antipsychotic medication. 10 
 11 
Aims 12 
We aimed to assess whether first-episode psychosis, which could be described as  ‘developing 13 
schizophrenia’, is associated with prediabetic markers, or ‘developing diabetes’, to determine whether 14 
intrinsic disease links could cause the conditions to develop in unison. 15 
 16 
Methods 17 
A systematic literature search was conducted using PRISMA criteria, searching Embase, Medline, 18 
PsychInfo, Web of Science and Google Scholar to 6th January 2016. We assessed case-control studies 19 
with biochemical assessment of prediabetic states in first episode psychosis patients alongside matched 20 
controls. 21 
 22 
Results 23 
Twelve studies were included in final analysis, including 1,137 participants. Several measurements were 24 
used to test for prediabetes, including fasting plasma glucose, impaired glucose tolerance and insulin 25 
resistance (measured by the homeostatic model assessment). Pooled analysis found first-episode 26 
psychosis to be related to impaired glucose tolerance (mean difference 1∙31 [0∙37, 2∙25]), insulin 27 
resistance (mean difference 0∙30 [0∙18,0∙42]) and the number of patients with impaired glucose tolerance 28 
(odds ratio 5∙44 [2∙63-11∙27]). 29 
 30 
Conclusion 31 
Our findings are suggestive of a potential link between prediabetic markers, in particular impaired 32 
glucose tolerance and insulin resistance, and first episode psychosis. However, we cannot establish 33 
causality, and the studies contributing to this review were at some risk of bias. Nevertheless, the findings 34 
may help to explain the increased prevalence of T2DM in patients with schizophrenia and could have 35 
implications for the management of schizophrenia patients.  36 
 37 
Introduction 38 
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 1 
Patients with schizophrenia have shortened life expectancy, with mortality rates twice that 2 
of the general population1. Causes for this extend beyond suicide, accidents and risk-taking 3 
behaviour2. Epidemiological evidence indicates that physical illnesses, including 4 
cardiovascular disease and type 2 diabetes mellitus2 (T2DM) account for a majority of the 5 
increased mortality risk.  The prevalence of T2DM in schizophrenia is increased by around 6 
one-third compared with the general population3. Many psychotropic medications affect 7 
metabolic parameters including glycaemic control4. However, recent research suggests 8 
intrinsic pathophysiological processes beyond the effects of medication, lifestyle and access 9 
to healthcare5. 10 
 11 
Diabetes was thought to be associated with mental disorders long before the discovery of 12 
Chlorpromazine in the 1950’s6. This older body of work was largely overlooked by studies 13 
in early schizophrenia psychopharmacology, which focused instead on the metabolic effects 14 
of medications. There is renewed interest in this area, with consideration of the role of 15 
inflammation7-9. 16 
 17 
Poor glycaemic control in T2DM correlates with levels of inflammatory cytokines including 18 
C-reactive protein (CRP), Tumour Necrosis Factor-α (TNF-α), Interleukin-6 (IL-6) and -1β 19 
(IL-1β) in the circulation10-12,. Mouse gene knock-out studies implicate a specific 20 
neuroinflammatory component to T2DM and peripheral insulin resistance and impaired 21 
glucose tolerance can be induced by hypothalamic inflammation mediated by TNF-α and 22 
IL-613. Several studies have also shown the benefit of anti-inflammatory medication in 23 
T2DM14,15. 24 
 25 
Similarly, evidence for an inflammatory component in mental disorders is accumulating, as 26 
in depression16, bipolar affective disorder17 and schizophrenia; Increased serum levels of IL-27 
1β, CRP and TNF-α in those with schizophrenia have been found18,19, and raised CRP and 28 
IL-6 levels in childhood may predict psychotic illness in later life20. Additionally, 29 
antipsychotics are known for their immunomodulatory and anti-inflammatory effects, and 30 
studies involving anti-inflammatory agents as treatment adjuncts have shown promise21. 31 
Raised levels of IL1, IL6 and TNFα have also been found in schizophrenia patients with 32 
metabolic syndrome22, compared with normo-glycaemic schizophrenia patients and healthy 33 
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controls, suggesting that there may be a common association between inflammation, 1 
dysglycaemia and schizophrenia.  2 
 3 
There has also evidence of genetic susceptibility to both conditions. Mutations in genes 4 
encoding for inflammatory markers such as TNF-α, IL-6, phospholipase A2, and the HLA 5 
complex, are found in both T2DM and schizophrenia23. Although there are clear differences 6 
between systemic and neuro-inflammation due to the blood brain barrier, evidence suggests 7 
that there may be a common pathway. Cytokines are thought to cross the blood brain 8 
barrier24, and its permeability may be increased in hyperglycaemic states, as shown in both 9 
animal25 and human26 models. 10 
 11 
First-Episode Psychosis (FEP), though a standalone diagnosis, may progress to 12 
schizophrenia, and therefore the study of FEP may advance our knowledge of the 13 
pathophysiology of schizophrenia. The study of FEP patients, who are generally younger 14 
with less physical comorbidity, also avoids the potential confounding by antipsychotic 15 
medication on glycaemic control.  16 
 17 
A previous systematic review27 assessed the prevalence of metabolic syndrome in FEP with 18 
or without antipsychotic medication, concluding that T2DM, as well as other elements of 19 
the metabolic syndrome, were uncommon in un-medicated FEP. However, this study only 20 
considered established cases of T2DM, and not those with markers of less severe glucose 21 
dysregulation such as impaired glucose tolerance or insulin resistance. As postulated by 22 
Fernandez-Egea et al (2013)28, glucose intolerance exists on a continuum, and subclinical 23 
dysglycaemia may only be identifiable after a glucose challenge. This less severe degree of 24 
impairment, termed ‘prediabetes’, was reported in many of the studies of glucose regulation 25 
in schizophrenia patients that antedated modern antipsychotics29. 26 
 27 
Given this evidence and the potential implications for the understanding and management of 28 
both conditions, we conducted a systematic review of clinical evidence, proposing that due 29 
to shared inflammatory pathways, FEP and prediabetic states may be linked. We attempted 30 
to ascertain the possibility of a link between prediabetes and FEP, on the grounds that these 31 
may represent ‘developing’ states of T2DM and schizophrenia, respectively. We have been 32 
unable to locate a systematic review examining this research question. 33 
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 1 
Methods 2 
A systematic literature search was conducted. The hypothesis stated that biochemical 3 
measures of prediabetic states would be more commonly found in antipsychotic naïve 4 
patients experiencing their first episode of schizophrenia spectrum psychosis than in healthy 5 
matched controls. 6 
 7 
OvidSP was used to search EMBASE (1947-present), MEDLINE (1946-present) and 8 
PsychInfo (1806-present) to 6th January 2016. Web of Science was searched from inception 9 
to 6th January 2016. We also searched the first twenty pages of Google Scholar (as 10 
recommended in a recent review30), alongside searching references of included studies. The 11 
search strategy, appearing in full in Appendix 1, was developed in association with an 12 
Information Specialist. MeSH headings or their equivalent, and text word terms were used. 13 
Inclusion and exclusion criteria are shown in tables 1 and 2 respectively. 14 
 15 
We applied the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-16 
analyses) guidelines35 for assessing search results.  17 
 18 
Titles and abstracts were screened independently by two authors (BP and GM). Full texts 19 
were screened by two reviewers independently (BP and GM). Discrepancies were resolved 20 
in consultation with a third author (KR). 21 
 22 
Data were extracted by two reviewers from studies that met the inclusion criteria (BP and 23 
GM). Quality appraisal was conducted using the Newcastle Ottawa Scale36 for case-control 24 
studies. Disagreements between the review authors over the risk of bias were resolved 25 
through discussion, with involvement of a third author (KR) if necessary. Publication bias 26 
was examined using funnel plots to test for asymmetry. 27 
 28 
The searches were re-run immediately prior to the final analyses, and further studies 29 
retrieved for inclusion using the processes outlined above.  30 
 31 
For continuous variables, the mean and standard deviations for each outcome and number in 32 
each group were entered into a meta-analysis programme (RevMan 5.3), with mean 33 
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differences and 95% confidence intervals between cases and controls calculated and 1 
displayed in forest plots. The inverse variance method was used where the weight given to 2 
each study was the inverse of the variance of the effect estimate. For dichotomous 3 
outcomes, the number of events and number in each group were entered into RevMan 5.3 4 
and the Mantel-Haenszel method used to pool studies. Fixed effects models were used to 5 
pool data unless there was substantial heterogeneity (I2>50%) when a random effects model 6 
was used. 7 
 8 
 9 
Role of the Funding Source 10 
The authors received no funding for the completion of this work. 11 
 12 
Results 13 
Electronic searches identified 1,436 studies (Fig 1); 1,015 after removal of duplicates. 989 14 
excluded at this stage. Twenty-six were shortlisted for full text retrieval, with twelve 15 
meeting the inclusion criteria37-48.  16 
 17 
Eleven47-51 of twelve were case-control studies. One was a randomised controlled trial48, 18 
though data were available at baseline for FEP patients and healthy matched controls, and so 19 
this study was treated as a case control study in the analyses. Table 3 outlines study 20 
characteristics. 21 
 22 
Sample size ranged from 5241to 14943, with 1,137 participants included in total. The 23 
majority of studies recruited an equal number of cases and controls. Average age across 24 
studies was 28∙8.  Age and gender was well matched between cases and controls in all 25 
studies. Across all studies, there was male predominance (overall 64% male).  26 
 27 
Included studies featured a varied definition of ‘antipsychotic naïve’. Several stipulated no 28 
prior exposure to antipsychotic medication37,39,40,42,46,48, whereas others38,43,47 stipulated a 29 
maximum antipsychotic prescription length of one week, with nil taken in the last thirty 30 
days. 31 
 32 
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All studies used DSM-IV criteria. Most used clinical diagnosis (from patient records) only, 1 
though five39,42,43,45,47 used the Structured Clinical Interview for DSM-IV (SCID) to clarify 2 
the diagnosis. However, studies differed in the definition of FEP. Whilst several37,38,42,45 3 
included patients with a first hospital presentation of schizophrenia spectrum disorder, 4 
two40,46 specified a first presentation meeting diagnostic criteria for schizophrenia only. Two  5 
studies43,537 subdivided their participants into ‘deficit’ and ‘non-deficit’ schizophrenia. 6 
 7 
Recruitment methods for control group selection were similar. Eleven studies screened for 8 
the absence of physical and mental ill health. One48 screened only for matched 9 
demographics. Recruitment was achieved in a variety of ways, from advertising in 10 
universities37,41,42,45, to local advertising38,39,47, to advertising in the hospital40,44,46. One 11 
study.48 did not report their recruitment strategy, though stated they included ‘matched 12 
healthy controls’. 13 
 14 
Table 4 outlines which biomarkers of prediabetes were used in each study. 15 
 16 
All twelve studies measured FPG. Pooling this data showed that there was no significant 17 
difference in FPG between those with FEP and controls. (mean difference 0∙03 mmol/L, 18 
95% CI -0∙04,0∙09 p=0∙43), (fig 2). 19 
 20 
Nine studies measured the HOMA (fig 3). The pooled data showed that insulin resistance 21 
was significantly higher in those with FEP than controls (mean difference 0∙30 units, 95% 22 
CI 0∙18,0∙42 p=<0∙0001). We were unable to pool data from one study37, which were 23 
presented as medians and ranges. In this study the effect size was; cases (effect size 1∙84, 24 
95%CI 0∙43,2∙67), controls (effect size 0∙92 (0∙27-16∙64)(p=<0∙01). 25 
 26 
Seven studies used the OGTT to measure IGT (fig 4). Pooling the data suggested increased 27 
IGT in FEP patients (mean difference 1∙31mmol/L, 95% CI 0∙37,2∙25 p=<0∙0001). There 28 
was a high level of heterogeneity in this analysis led by one outlier, so a random effects 29 
model was used.  30 
 31 
Seven studies compared the number of patients meeting criteria for IGT between cases and 32 
controls (fig 5.) Pooled data show a greater number of FEP participants met the criteria for 33 
IGT than controls (OR 1∙31, 95% CI 2∙63,11∙27 p=<0∙0001).  34 
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 1 
We also performed an analysis of the 7 studies with both measures of FPG and IGT, and the 2 
findings are still non-significant for fasting glucose. There was no consistent pattern in the 7 3 
studies. (effect estimate 0∙07, 95% CI -0∙03, 0∙16). 4 
 5 
Many studies measured a battery of other metabolic indices to assess for the metabolic 6 
syndrome as a whole. To test that our glycaemic findings aren’t related to wider metabolic 7 
abnormalities in the included studies, we performed analyses on the other aspects of the 8 
metabolic syndrome tested (appendix 2). These analyses show no significant difference 9 
between cases and controls in LDL, triglycerides, BMI and waist circumference. Both total 10 
and HDL cholesterol were significantly greater in controls than cases.  11 
 12 
Studies were appraised using the Newcastle Ottawa Scale36 (NOS) for case-control studies. 13 
Studies scored between 4 and 8, out of a possible 9. Appendix 3 presents the NOS 14 
assessment for each study. There was variability between studies for each of the quality 15 
assessment domains; selection, comparability and exposure. Only 4 of 12 studies scored 16 
maximum points for selection and 7 of 12 for comparability.  17 
 18 
Only one study48 returned results of the OGTT that were not in favour of the hypothesis. 19 
This study also scored the minimum of four in the NOS. This RCT was also the only study 20 
that did not report the recruitment strategy for control subjects. Removing this study in a 21 
sensitivity analysis reduced heterogeneity to 0% and increased the effect size (mean 22 
difference 1.61, 95% CI 1.3, 1.92).  In addition, both studies with the highest recorded score 23 
of eight37,47 found results wholly in support of the hypothesis. 24 
 25 
We explored publication bias using a funnel plot for FPG, which was the only outcome with 26 
sufficient studies to do so (n=12) (Appendix 4). There was no obvious asymmetry, but the 27 
number of studies with which to explore this formally was limited. 28 
 29 
 30 
 31 
 32 
 33 
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Discussion 1 
 2 
We aimed to examine whether an association exists between FEP and prediabetes, possibly 3 
due to shared inflammatory processes. To our knowledge, this is the first systematic review 4 
and meta-analysis addressing this question. 5 
 6 
In line with other published work27, patients with FEP did not have significantly impaired 7 
FPG compared with matched controls (fig 2). However, our findings show an association 8 
between FEP and prediabetic states measured by IGT and HOMA.  9 
 10 
A number of studies37,38,39,41,43,45,48 expressed IGT as simply the number of cases and 11 
controls who met WHO/ADA criteria for IGT (using OGTT), demonstrating higher levels 12 
of IGT in cases. However, the binary of with/without IGT may not adequately describe the 13 
spectrum of IGT, and may therefore be less sensitive.  14 
 15 
Another frequently measured parameter of prediabetes by studies was the HOMA. The 16 
relationship between glucose and insulin levels depends upon the balance between hepatic 17 
glucose production and pancreatic insulin secretion. The original model49 (HOMA1) 18 
provides a simple mathematical equation to estimate insulin resistance. An improved, 19 
computerised model (HOMA2) was later developed and is preferable to HOMA1
33. Our 20 
pooled analysis for the HOMA method shows that insulin resistance is more common in 21 
patients with FEP than in matched controls, with a low degree of heterogeneity. Seven 22 
studies use the HOMA1 equation, with one
38 using the more precise HOMA2 model. One
37 23 
did not state which model was used. Our findings also show that the effect sizes between 24 
FEP and IGT are greater than with insulin resistance. This may be explained by the use of 25 
the less sensitive HOMA1 equation in many studies, though the possibility of difference in 26 
disease process is possible. 27 
 28 
Analyses of other elements of the metabolic syndrome returned two significant results, with 29 
HDL (albeit with relatively high heterogeneity) and total cholesterol higher in controls. The 30 
higher total cholesterol may be a by-product of a higher ‘cardio-protective’52 HDL 31 
component in controls. It may however raise questions around the selection of ‘healthy’ 32 
controls, and relate to the relatively high prevalence of undiagnosed familial 33 
hypercholesteraemia in the general population53. It is likely that many non-34 
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anthropomorphically matched potential controls had been screened out of inclusion, thus 1 
reducing the potential generalizability of our results. However, one might argue that 2 
matching in this manner is preferable, to help control for the confounding effect of poor diet 3 
and general health on glycaemic parameters. Contrarily, lower cholesterol may feature as 4 
part of the metabolic abnormality seen in FEP. It would be insensible to speculate further 5 
here, though this finding may warrant further attention in future. Finally, since a lower 6 
number of studies measured the other metabolic indices, there is a higher likelihood of 7 
confounding. 8 
 9 
Strengths and Limitations 10 
We present findings to suggest that the glycaemic abnormalities associated with FEP may 11 
be intrinsic, and extend beyond the known effects of medication, lifestyle and access to 12 
healthcare. It is possible that these findings could represent a similar association in 13 
schizophrenia. Some might term FEP a ‘developing’ schizophrenia, and others might term 14 
prediabetes a ‘developing’ diabetes, hence the results might suggest that the two conditions 15 
do indeed develop in unison.  The results may suggest further research is warranted into a 16 
possible intrinsic link between diabetes and schizophrenia. As previously noted, 17 
examination into the metabolic effects of psychiatric disease is better conducted on 18 
participants that have not yet been exposed to potentially confounding medication, which 19 
renders FEP patients, who are also generally younger (with less comorbid medical 20 
conditions), a valid cohort to study. 21 
 22 
However, there are several limitations that must be considered. Firstly, case-control studies 23 
are intrinsically susceptible to selection bias arising from a number of sources, as 24 
demonstrated in the NOS scores for the majority of studies. Whilst recall bias should be 25 
minimised due to screening participants and controls equally, and observer bias minimised 26 
due to the objectivity of biochemical assessment, the nature of recruitment of the control 27 
group was not always fully reported in included studies. 28 
 29 
Publication bias is another limitation to be considered. Whilst we did not exclude 30 
unpublished results, theses or conference abstracts in our search, only published studies met 31 
inclusion criteria. However, visual inspection of the funnel plots revealed no obvious 32 
asymmetry. Furthermore, glycaemic status was but one outcome measure in studies equally 33 
examining other aspects of the metabolic syndrome.  34 
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 1 
None of the studies report how many potential participants were initially screened from 2 
taking part in the respective studies. This may be pertinent in light of the non-significant 3 
findings of certain other elements of the metabolic syndrome (i.e. BMI, lipid metabolism, 4 
waist circumference), which may be associated with physical illness and the need to take 5 
physical medication. This may have resulted in being screened from inclusion, potentially 6 
causing sampling bias. 7 
 8 
Problems with confounding may also reduce confidence in the results. All included studies 9 
were either observational or included with data used in the manner of an observational 10 
study, and are thus prone to confounding. We cannot establish causality with data from case 11 
control studies, rather an association between FEP and pre-diabetic markers. Meta-analyses 12 
of observational studies are known to be less reliable than with randomised controlled 13 
trials50 and the results should therefore be interpreted with caution. 14 
 15 
Inclusion criteria also differed. Whilst one study40 followed its ‘case’ group for six months 16 
after data collection to ensure diagnostic stability of first-episode schizophrenia , others 17 
were less strict, accepting all patients with first episode schizophrenia spectrum disorder. 18 
Confidence in diagnosis might therefore be lower in these studies. 19 
 20 
Studies also varied in their definition of ‘antipsychotic naïve’. Whilst the majority specified 21 
cases to have no prior exposure to antipsychotic medication, three38,43,47 stipulated that cases 22 
may have taken antipsychotics for a maximum of one week, with none in the thirty days 23 
prior to the study. Results from these studies38,43,47 were broadly in line with the results from 24 
studies with stricter definitions of ‘antipsychotic naïve’. Although reasonable attempts were 25 
made to minimise exposure to antipsychotic medication prior to assessment, any exposure 26 
could lead to confounding. However, the sole RCT48  measured FPG following an OGTT at 27 
six and fourteen weeks after included participants were prescribed one of four commonly 28 
used antipsychotics, and found no significant elevation in either FPG or two-hour glucose at 29 
six weeks. These findings help to support the assertion that minimal past exposure to 30 
antipsychotic medication as described here may be unlikely to confound the results of this 31 
review. 32 
 33 
Furthermore, severity of symptoms is not widely addressed. Most studies recruited FEP 34 
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patients from a hospitalised population, from which one may deduce that participants were 1 
experiencing relatively severe symptoms. However, all participants were required to provide 2 
written informed consent to take part in their respective studies, which may have excluded 3 
patients with the most severe forms of illness causing impaired capacity to enter the study. 4 
Research suggests that even within the spectrum of schizophrenia disorders there may be 5 
differences in glycaemic control. This was proposed by Kirkpatrick et al (2009)47, in which 6 
those patients with ‘nondeficit’ drug-naive schizophrenia had a significantly higher two-7 
hour glucose level than those with ‘deficit’ schizophrenia. It could be argued then, that if 8 
such differences in pre-treatment glycaemic control exist as part of the spectrum of 9 
schizophrenic illness, the inclusion of a quantitative assessment of symptoms would be 10 
beneficial. Relevance of illness severity may be appropriate in light of a previous systematic 11 
review by Perry et al (in submission)51, which found that although all studies were 12 
observational in nature, poor glycaemic control was consistently related to greater 13 
schizophrenia severity, as measured by symptom score or cognitive function.  This finding 14 
was based on cross-sectional analyses, and was therefore prone to confounding and reverse 15 
causality, as well as selection bias.  16 
 17 
Inclusion criteria for controls may also predispose to confounding. Whilst recruitment was 18 
mostly homogenous across studies, one did not report their method of recruitment. As the 19 
comparator across studies was healthy matched controls, rather than subjects with other 20 
types of mental illness, there is the possibility that any association derived from the results 21 
may not specifically be due to first episode psychosis, rather mental distress. 22 
 23 
There is also the possibility that our results have occurred by chance. A potential 24 
contributing factor on glucose regulation in an acutely stressed state is cortisol. Though we 25 
did not examine cortisol as an outcome measure in our pooled analyses, this was discussed 26 
by a number of the  studies. Five measured early morning cortisol and included it as part of 27 
their covariate analyses37-39,41,47. Of these, two reported significantly raised cortisol39,41 28 
whereas three studies reported no significant difference37,38,47.  The finding that insulin 29 
resistance in FEP patients is abnormal compared with healthy matched controls even when 30 
cortisol and fasting glucose levels are accounted for provides strong evidence that 31 
hypercortisolaemia cannot fully account for the findings in this review, though further 32 
research in this area would be beneficial. 33 
 34 
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Finally, whilst we have presented that FEP may constitute a ‘developing schizophrenia’, this 1 
may be inaccurate. FEP and schizophrenia remain separate diagnostic entities, and not all 2 
sufferers of FEP will progress to schizophrenia. Nevertheless, the pathophysiology of 3 
psychosis may be shared between the two diagnoses, and secondly, the study of FEP as 4 
schizophrenia may be the only ethical way to study un-medicated patients, since 5 
antipsychotic medication can inherently affect glycaemic indices. 6 
 7 
Conclusions 8 
 9 
Our findings may suggest an association between markers of prediabetes, which might be 10 
termed a ‘developing’ diabetes, and FEP, which might be termed a ‘developing’ 11 
schizophrenia. 12 
 13 
The FEP participants across all studies were relatively young, physically healthy, and had 14 
not been treated with antipsychotic medication for a period before the study (though this 15 
varied between studies), meaning the potential confounding variables were reduced. Our 16 
findings cannot therefore rule out the possibility that schizophrenia and diabetes share 17 
intrinsic disease links, which may be inflammatory in nature. This may warrant further work 18 
in future. 19 
 20 
Moreover, our findings may suggest that if patients are at an increased risk of developing 21 
glycaemic regulation abnormalities even prior to the administration of antipsychotics, 22 
heightened vigilance and stricter control of the metabolic indices of patients is essential to 23 
help reduce the physical health burden associated with the disease. 24 
 25 
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Original clinical studies examining the co-existence of a first-episode psychosis with prediabetes. 
Patients over the age of sixteen (to ensure diagnostic accuracy in the face of rarer occurrence 
below this age) having presented to services with a diagnosis matching a first presentation of 
psychosis, as per study criteria; based upon a specific diagnostic classification (DSM/ICD) for 
first-episode psychosis. 
Patients defined as being ‘antipsychotic naïve’ or ‘antipsychotic free’ at the time of assessment, 
as per study criteria. 
As a primary measure, quantitative assessment of prediabetes defined as per specific diagnostic 
criteria by World Health Organisation (WHO)31 / American Diabetic Association (ADA)32 
o Impaired Fasting Glucose (IFG) – Defined as a fasting plasma glucose (FPG) of 
5.6-6.9mmol/L 
o Impaired Glucose Tolerance (IGT) – Defined as a plasma glucose two-hours 
following administration of 75g glucose as part of an Oral Glucose Tolerance Test 
(OGTT) of 7.8-11.0mmol/L 
In addition to WHO/ADA criteria which focus on common clinical measures for prediabetes, 
studies were included that used the Homeostatic Model Assessment (HOMA), a sensitive 
mathematical means of estimating insulin resistance from FPG and insulin levels, commonly 
used in observational and interventional research relating to glycaemic control33,34. 
HbA1c, which is included in WHO criteria31, was not measured as an outcome, due to reported 
poor sensitivity32 in comparison to other measures.    
 1 
 2 
Studies that did not have a matched control group for comparison of glycaemic parameters. 
Studies including participants under the age of sixteen either in the patient or control group as the 
epidemiology of FEP rates are rare below this age, hence diagnostic accuracy in these patients 
might be reduced. 
 3 
 4 
 5 
 6 
 7 
 8 
Table 1: Inclusion Criteria 
Table 2: Exclusion Criteria 
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 FPG HOMA-IR 75g OGTT HbA1C Fasting Insulin 
Petrikis et al, (2015)42 x x  x  
Fernandez-Egea et al, (2009)43 x x x x  
Spelman et al, (2007)44 x x x x  
Arranz et al, (2004)45 x x    
Ryan et al, (2003)46 x x x   
Wu et al, (2013)47 x x    
Kirkpatrick et al, (2012)48 x  x   
Dasgupta et al, (2010)49 x x    
Sengupta et al, (2008)50 x x x   
Enez-Darcin et al, (2015)51 x x   x 
Kirkpatrick et al, (2009)52 x  x x x 
Wani et al, (2015)53 x  x   
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
Table 4: Biochemical measures of prediabetes 
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Figures  1 
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Fig 2. FPG in included studies 
Fig 1. Search flow diagram 
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Fig 3.HOMA-IR in included studies 
Fig 4.2hG in included studies 
Fig 5. No. Participants with IGT 
